Anavex Life Sciences Corp (AVXL)

[dia76ca]

The new patent shows the wide range of blarcamesines application!
"The neurological disease may be selected from cognitive impairment, Lewy body dementia, stroke, traumatic brain injury, infections, spinal cord injury, Alzheimer’s disease, Parkinson’s disease, dementia, Huntington’s disease, Amyotrophic lateral sclerosis, Prion disease, Rett Syndrome, Fragile X Syndrome, cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith -Magenis syndrome, multiple sclerosis, Fronto-temporal dementia, motor neuron disease (MND), spinocerebellar ataxia (SCA), spinal muscular atrophy (SMA), autism spectrum disorder, schizophrenia, post-traumatic stress disorder (PTSD), and any combination thereof."